Pay in 4 interest-free payments of $6.46 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
Key Benefits Observed in Clinical Trials Treatment of Erythropoietic Protoporphyria (EPP): MT-1 (Afamelanotide) is FDA-approved for use in patients with EPP, a rare genetic disorder that causes extreme photosensitivity, leading to severe pain and skin damage upon light exposure
Further studies are warranted to better characterize this potential adverse effect and guide agent selection in patients at risk for SIBO
If you are feeling stressed , anxious, or depressed (or maybe a bit of all three), getting help can make you feel better and less hungry
Inform your doctor if you are taking any other medicines or if you are pregnant or breastfeeding
10.1055/s-2004-821225 38
US$ 26.48
US$ 22.84
US$ 29.34
US$ 21.21
